Dr Stefan Anker: Patients With HFpEF Deserve a New Treatment

September 21, 2021 07:00pm

With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction (HFpEF) is possible, said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study.

A Timeline of COVID-19 Vaccine Developments for the Second Half of 2021

September 21, 2021 06:15pm

Study Finds Inverse Relationship Between OSA, Male Testosterone Levels

September 21, 2021 06:00pm

COVID-19 Symptoms Can Differentiate Respiratory Diseases, Study Says

September 21, 2021 04:50pm

Ruxolitinib Likely Safe, Effective in Chronic GVHD

September 21, 2021 04:48pm

Read the August issue of AJMC

Read about Amazon Pharmacy, the impact of television advertising on Marketplace insurance, and more

Spotlight on CAR T-Cell Therapy

We interview experts on investigational treatments such as liso-cel, and ask how to bring them to community practice.

AJMC® Profiles in Care Launches

This AJMC® Profiles in Care provides an in-depth look into the results of the outcomes-based agreement between Boehringer Ingelheim and Highmark Inc.

Product Profiler: PEPAXTO

This publication is designed for payers, formulary committees, or other similar entities with knowledge and expertise in the area of healthcare economics making decisions regarding access, coverage, and reimbursement for PEPAXTO.

A Timeline of COVID-19 Vaccine Developments in 2021

If 2020 was dominated by the news of how COVID-19 spread across the globe, then 2021 has so far been focused on ending the pandemic through vaccine distribution.

Coverage of European Respiratory Society International Congress 2021

View news from the ERS International Congress 2021, including session summaries, poster write-ups, and interviews with key opinion leaders

Spotlighting Pandemic-Related Challenges, Data-Driven Solutions for Payers

September 21, 2021

Podcast

On this episode of Managed Care Cast, we address how delays in routine care and other aspects of the pandemic are affecting payer organizations today, and how technology innovations like natural language processing can work to empower key initiatives in population health and beyond.

What We're Reading: Supreme Court Sets Abortion Case Date; Workplace Safety Rule for Extreme Heat; Rehab and Stroke Recovery

September 21, 2021

Article

The Supreme Court announces it will hear arguments for Mississippi’s case to overturn the landmark Roe v Wade decision on December 1; the Biden administration aims to address extreme heat conditions in the workplace; rehab timing may affect stroke recovery.

PCOS Estimated to Cost $8 Billion in Immediate, Long-term Health Issues

September 21, 2021

Article

An updated report shows that the long-term cost of treating the health effects of polycystic ovary syndrome (PCOS)—$4.3 billion—is even higher than $3.7 billion it takes to diagnose and treat immediate issues that present for women who are of reproductive age.

Managing the Surge: Delayed Chronic Wound Care During COVID-19

September 21, 2021

Article

Study Underscores Importance of Depression Screening, Treatment in COPD

September 20, 2021

Article

Results of a longitudinal study outline the relationship between depression and patients reported outcomes among those with chronic obstructive pulmonary disease (COPD).

Development of Myopia Found to Accelerate in Young Schoolchildren Amid Pandemic

September 20, 2021

Article

Incidence and risk of myopia development were found to rise significantly among young Chinese schoolchildren who were exposed to environmental changes caused by COVID-19 between grades 2 to 3.

FDA Approves First Biosimilar for Lucentis

September 20, 2021

Article

Byooviz becomes the first FDA-approved ophthalmology biosimilar and the first FDA-approved biosimilar referencing Lucentis (ranibizumab), according to a statement from developers Samsung Bioepis and Biogen.

Encourage Further SGLT2 Inhibitor Treatment for Diabetes, Kidney Disease, Expert Says

September 20, 2021

Article

New data from the CREDENCE trial shows that the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin may reduce hyperkalemia risk in people with type 2 diabetes and chronic kidney disease who are using RAAS inhibitors.

What We’re Reading: Pfizer Underscores Vaccine Safety; COVID-19 Vaccine Efficacy Updated; Democrats Push Health Care Reforms

September 20, 2021

Article

Pfizer says a newly formulated dose of its vaccine is safe and effective in children; CDC data underscore the efficacy of the 3 COVID-19 vaccines; Biden aims to reform health care with trillion-dollar package.

Diagnostic Process for Individuals With Suspected AD

September 20, 2021

Video

A discussion on the typical journey of a patient with Alzheimer disease from initial presentation to proper diagnosis within the health care system.